Optimizing weight control in diabetes: antidiabetic drug selection

S Kalra1, B Kalra1, AG Unnikrishnan2, N Agrawal3, S Kumar41Bharti Hospital, Karnal; 2Amrita Institute of Medical Science, Kochi; 3Medical College, Gwalior; 4Excel Life Sciences, Noida, IndiaDate of preparation: 18th August 2010Conflict of interest: SK has received speaker fees from Novo Nordisk, san...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S Kalra, B Kalra, AG Unnikrishnan, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/780c84b46b5e4852bc66635152f4d5b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:780c84b46b5e4852bc66635152f4d5b5
record_format	dspace
spelling	oai:doaj.org-article:780c84b46b5e4852bc66635152f4d5b52021-12-02T07:37:56ZOptimizing weight control in diabetes: antidiabetic drug selection1178-7007https://doaj.org/article/780c84b46b5e4852bc66635152f4d5b52010-08-01T00:00:00Zhttp://www.dovepress.com/optimizing-weight-control-in-diabetes-antidiabetic-drug-selection-a5090https://doaj.org/toc/1178-7007S Kalra1, B Kalra1, AG Unnikrishnan2, N Agrawal3, S Kumar41Bharti Hospital, Karnal; 2Amrita Institute of Medical Science, Kochi; 3Medical College, Gwalior; 4Excel Life Sciences, Noida, IndiaDate of preparation: 18th August 2010Conflict of interest: SK has received speaker fees from Novo Nordisk, sanofi-aventis, MSD, Eli Lilly, BMS, and AstraZeneca.Clinical question: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes?Results: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control.Implementation: &bull; Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.&bull; Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.Keywords: weight control, diabetes S KalraB KalraAG Unnikrishnanet alDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 297-299 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 S Kalra B Kalra AG Unnikrishnan et al Optimizing weight control in diabetes: antidiabetic drug selection
description	S Kalra1, B Kalra1, AG Unnikrishnan2, N Agrawal3, S Kumar41Bharti Hospital, Karnal; 2Amrita Institute of Medical Science, Kochi; 3Medical College, Gwalior; 4Excel Life Sciences, Noida, IndiaDate of preparation: 18th August 2010Conflict of interest: SK has received speaker fees from Novo Nordisk, sanofi-aventis, MSD, Eli Lilly, BMS, and AstraZeneca.Clinical question: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes?Results: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control.Implementation: &bull; Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.&bull; Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.Keywords: weight control, diabetes
format	article
author	S Kalra B Kalra AG Unnikrishnan et al
author_facet	S Kalra B Kalra AG Unnikrishnan et al
author_sort	S Kalra
title	Optimizing weight control in diabetes: antidiabetic drug selection
title_short	Optimizing weight control in diabetes: antidiabetic drug selection
title_full	Optimizing weight control in diabetes: antidiabetic drug selection
title_fullStr	Optimizing weight control in diabetes: antidiabetic drug selection
title_full_unstemmed	Optimizing weight control in diabetes: antidiabetic drug selection
title_sort	optimizing weight control in diabetes: antidiabetic drug selection
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/780c84b46b5e4852bc66635152f4d5b5
work_keys_str_mv	AT skalra optimizingweightcontrolindiabetesantidiabeticdrugselection AT bkalra optimizingweightcontrolindiabetesantidiabeticdrugselection AT agunnikrishnan optimizingweightcontrolindiabetesantidiabeticdrugselection AT etal optimizingweightcontrolindiabetesantidiabeticdrugselection
_version_	1718399290216284160

Optimizing weight control in diabetes: antidiabetic drug selection

Ejemplares similares